Mounjaro vs Ozempic vs Wegovy: Which Is Best for Weight Loss?

The quick version

• Mounjaro is the brand name for tirzepatide.
• Ozempic and Wegovy are both the brand names for the same drug, semaglutide.

Yes, really. Ozempic and Wegovy are the same active ingredient made by the same company. The difference is what each one is licensed for and the dose it builds up to. Ozempic is licensed to treat type 2 diabetes. Wegovy is licensed specifically for weight loss. So when your goal is weight management, the honest head-to-head is Mounjaro vs Wegovy, with Ozempic sitting slightly to one side.

How they work (and why one targets more)

All three belong to a family of medicines that copy your gut's natural appetite hormones. If you want the full mechanism, we cover it in how Mounjaro works and in our overview of GLP-1 medications explained. The short version:

• Semaglutide (Ozempic, Wegovy) mimics one hormone, GLP-1. GLP-1 tells your brain you are full and slows how fast your stomach empties.
• Tirzepatide (Mounjaro) mimics two hormones, GLP-1 and GIP. That dual action is the single biggest reason it tends to edge ahead on average weight loss.

Think of it like turning down the volume on hunger. Semaglutide turns down one dial. Tirzepatide turns down two.

The comparison table

Here is everything side by side.

A quick note on that last row: Ozempic is not licensed for weight loss, so it has no weight-management dose to quote. People do lose weight on it because it is the same drug as Wegovy, but at a licensed diabetes dose rather than a higher weight-loss one.

What the evidence actually shows

This is where averages matter, so let us be precise rather than breathless.

In the SURPASS-2 trial, tirzepatide was compared directly against semaglutide in people with type 2 diabetes. Tirzepatide came out ahead on both blood-sugar control and weight loss. That is one of the few genuine head-to-head studies, and it is why tirzepatide earned its reputation.

For weight loss specifically, we mostly compare across separate trial programmes:

• In the SURMOUNT programme, tirzepatide at the highest dose produced average weight loss of around 20% or more of body weight over roughly 72 weeks, alongside lifestyle changes.
• In the STEP programme, semaglutide at the weight-loss dose produced average weight loss of around 15% over a similar period, again with lifestyle support.

Two honest caveats before you read too much into those numbers:

1. These are averages, and the range is huge. Some people on semaglutide out-lose the average tirzepatide user. Your starting weight, dose, diet, activity and genetics all move the result.
2. Cross-trial comparisons are not perfect. SURMOUNT and STEP were run separately, with different participants. The direct SURPASS-2 comparison is stronger evidence than lining two trials up next to each other.

So the fair summary is: tirzepatide tends to produce more weight loss on average, but the medicine that works best is the one that suits your body and that you can actually stick with.

Not sure which, if any, of these is right for you? A regulated pharmacy consultation can check your eligibility, review your health history and, if appropriate, recommend a suitable option with a proper titration plan.

Side effects: broadly similar

Because all three work on the same appetite pathways, they share a similar side-effect profile. The common ones are digestive: nausea, constipation, diarrhoea and feeling full quickly, especially in the early weeks as the dose steps up.

Most of these ease as your body adjusts, and starting low and building slowly is exactly how clinicians keep them manageable. We go through the practical detail, and how to reduce them, in our guide to side effects. None of these medicines are gentle enough to take casually, which is the whole reason they are prescription-only.

One targets a single hunger hormone. The other targets two. That difference shows up on the scales.

So which should you choose?

Here is the reframe: you do not really choose. A prescriber does, with you, based on your health rather than a headline number.

• If maximum average weight loss is the priority and you tolerate it well, tirzepatide (Mounjaro) has the edge in the data.
• If you respond well to semaglutide, or it suits your circumstances better, Wegovy is a strong, well-established option.
• Ozempic is really a diabetes medicine. Using it for weight loss alone is off-licence, and supply is often reserved for people with diabetes.

Cost, availability, how you cope with side effects and any other conditions you have can all tip the balance. That is not a cop-out. It is the reason two people with the same weight can be advised toward different medicines.

The bottom line

Mounjaro, Ozempic and Wegovy are not three separate miracles. They are two active ingredients: tirzepatide, which targets two hormones and tends to deliver larger average weight loss, and semaglutide, which targets one and is sold as Ozempic for diabetes and Wegovy for weight loss.

Whichever route fits you, the medicine is a tool, not a cure. The people who keep the weight off pair it with better eating, regular movement and honest medical support. The first step is simple: get a proper assessment. A regulated online pharmacy can check your eligibility in minutes and tell you, without the hype, whether any of these is right for you.